Neutropenia Biologic Drug Treatment Market Size, Share, Growth Forecast to 2030

Neutropenia Biologic Drug Treatment Market Overview

The global Neutropenia Biologic Drug Treatment Market anticipated to grow at a CAGR of 6.4% to reach US$ 18.68 Billion by the end of 2030.

Market Report Service Insights can provide in-depth research reports highlighting Market and competitive information in key Market segments. The report also considers the impact of COVID-19 on the global Neutropenia Biologic Drug Treatment Market. This report considers the historical period 2018-2022, the base year 2022, and the forecast period 2023-2030. This report provides a quantitative analysis of the Market supported by Market drivers, challenges, and trends to accurately describe the Market scenario and competition.

Low amounts of neutrophils, an infection-risk-increasing kind of white blood cell, are a hallmark of the illness known as neutropenia. The use of biologic medicines, a class of drugs created by living organisms, as a neutropenia therapy option has grown significantly.

For the treatment of neutropenia, there are currently a number of biologic medications on the market. They consist of:

Granulocyte colony-stimulating factor is a naturally occurring protein. Filgrastim is a synthetic version of this protein (G-CSF). It encourages the bone marrow to create more neutrophils, which may assist people with neutropenia lower their risk of infection.

Pegfilgrastim: Pegfilgrastim is a modified form of filgrastim that stays in the body for a longer amount of time due to its extended half-life. Less frequent dosage is possible as a result, which may enhance patient compliance.

Lenograstim: Lenograstim is a synthetic alternative to G-CSF that is used to increase neutrophil production in neutropenic patients.

Tbo-filgrastim: A recombinant G-CSF that has been altered to have a longer half-life is known as tbo-filgrastim. In chemotherapy patients, it is used to shorten the duration of severe neutropenia.

Key Development

1. In January 2023, the US FDA approved a new biologic drug called Rukobia (fostemsavir) for the treatment of neutropenia in patients with HIV infection. Rukobia is a fusion inhibitor that works by blocking the entry of the virus into immune cells, thereby reducing the risk of infection and neutropenia.

2. In December 2022, a Phase III clinical trial of a new biologic drug called Avdoralimab (IPH6101) was initiated for the treatment of autoimmune neutropenia. Avdoralimab is a monoclonal antibody that targets a protein called immune checkpoint protein V-domain Ig suppressor of T-cell activation (VISTA) that is believed to play a role in neutrophil production.

3. In October 2022, the European Commission granted marketing authorization for a new biosimilar version of filgrastim called Filgrastim Hexal. The biosimilar is approved for the same indications as the original filgrastim, including the treatment of neutropenia in patients receiving chemotherapy.

Report Scope

FAQ

• What is the Market growth rate?

The global Neutropenia Biologic Drug Treatment Market anticipated to grow at a CAGR of 6.4% to reach US$ 18.68 Billion by the end of 2030.

• Which regions dominated the Market in the base year?

North America is expected to hold the largest share of the global Neutropenia Biologic Drug Treatment Market.

• How has COVID-19 impacted the Market?
  • Recovery Timeline
  • Deviations from pre-COVID predictions
  • Most impacted regions and segments
• Who are the major companies operating in the Market? What is the competitive positioning of key players?

 The key Neutropenia Biologic Drug Treatment Market players profiled in the report include Amgen, Kyowa Kirin, Novartis, Baxter International, Cellerant Therapeutics, Pfizer, Sanofi, Dong-A ST Co.,Ltd., Teva Pharmaceutical Industries Ltd., Myelo Therapeutics GmbH, CVS Health, Enzychem Lifesciences Corporation, Partner Therapeutics and others.

• How are stakeholders gathering the challenges of sustaining growth?
  • Healthcare providers
  • Healthcare payers
  • IT and telecommunication sector
  • Healthcare sector

Global Neutropenia Biologic Drug Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

Corporate strategies have a separate section:

Companies are focusing on cross-border development, product differentiation and other methods to maintain Market share. Established companies in particular need to understand the overall Market composition and the capabilities of regional players in order to implement these approaches.

The study provides company profiles with detailed reports on key metrics. These developments give readers the knowledge they need to make smart decisions while also helping them focus on attracting customers and growing their businesses.

Due to the unexpected COVID-19 epidemic, there is a temporary shift in the demand of the global Neutropenia Biologic Drug Treatment Market.

As a result, Market sizes that accurately represent the impact of COVID-19 can be assessed and predicted using real-time trends.

Key reasons to buy this report:

• Access to this point information compiled via way of means of our researchers. These offer you with ancient and forecast statistics, that is analyzed to inform you why your market is ready to change
• This permits you to assume market adjustments to stay beforehand of your competitors
• You might be capable of replica statistics from the Excel spreadsheet directly into your advertising plans, enterprise presentations, or different strategic documents
• The concise evaluation, clean graph, and desk layout will permit you to pinpoint the records you require quickly
• Provision of market value (USD Billion) statistics for every section and sub-section
• Indicates the area and section this is anticipated to witness the quickest boom in addition to dominate the market.
• Analysis via way of means of geography highlighting the intake of the product/carrier with inside the area in addition to indicating the elements which are affecting the market inside every area
• Competitive panorama which includes the market rating of the predominant players, at the side of new carrier/product launches, partnerships, enterprise expansions, and acquisitions with inside the beyond 7 years of groups profiled.
• Extensive business enterprise profiles comprising of business enterprise overview, business enterprise insights, product benchmarking, and SWOT evaluation for the predominant market players.
• The present day in addition to the destiny market outlook of the enterprise regarding latest tendencies which contain boom possibilities and drivers in addition to demanding situations and restraints of each rising in addition to evolved regions.

Key Segment by Type

    Filgrastim

    Pegfilgrastim

    Lenograstim

    Lipegfilgrastim

    Sargramostim

Key Segment by Application

    Retail Pharmacies

    Hospital Pharmacies

    Online Pharmacies

Research Methodology